• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

JDRF backs GluSense with $2m grant

February 16, 2017 By Sarah Faulkner

GluSenseJDRF backs GluSense with $2m grant said yesterday that it received a $2 million grant from the Juvenile Diabetes Research Foundation’s T1D fund for the company’s injectable glucose sensor.

Israel-based GluSense, part of Rainbow Medical, is developing the Glyde continuous glucose monitor for patients with Type I diabetes. The device is injected under the skin and lasts for 1 year, according to the company, sending continuous glucose measurements wirelessly to a wearable device.

“Today, diabetic patients need to endure frequent finger pricks daily in order to manage their glucose level, and even with modern CGMs, frequent calibrations, measurement verifications and replacements are still a hassle and limit efficient treatment,” GluSense CEO Boaz Brill said in prepared remarks.  “In contrast, our Glyde continuous glucose monitor will provide accurate glucose measurement for a full year with significantly fewer blood glucose calibrations. This ground-breaking technology will simplify and improve the life of people living with T1D and insulin dependent T2D worldwide.”

“This collaboration is a significant recognition of the GluSense product and technology,” Rainbow Medical CEO Efi Cohen-Arazi added. “It will speed up our development process and ensure the technology meets the needs of patients and caregivers.”

GluSense plans to use the T1D Fund investment to bring the Glyde CGM closer to its 1st in-human clinical trial, the company reported.

The company’s implant uses a fluorescent glucose-sensitive biosensor, which is maintained with engineered live cells.

“The GluSense Glyde CGM is a highly innovative and promising technology,” T1D managing director Jonathan Behr said. “When paired with future advanced artificial pancreas systems or insulin injections, it will reduce the burden of T1D and help those living with the disease maintain blood glucose levels in a safe range.”

In January, the JDRF said that its T1D Fund made an unspecified equity investment in Bigfoot Biomedical and the Smartloop automated insulin delivery system it’s developing.

Bigfoot bills the Smartloop system as “the world’s first Internet-of-Things medical device system delivered as a monthly service,” designed to connect wearable insulin delivery and glucose monitoring systems controlled via smartphone.

Filed Under: Diabetes, Featured, Funding Roundup Tagged With: GluSense, Rainbow Medical

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS